• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

50 岁及以上血液恶性肿瘤患者行异基因造血干细胞移植的预后因素。

Prognostic factors in patients aged 50 years or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancy.

机构信息

Department of Hematology, Kanagawa Cancer Center, 1-1-2 Nakao, Asahi-ku, Yokohama 241-0815, Japan.

出版信息

Int J Hematol. 2012 Mar;95(3):291-8. doi: 10.1007/s12185-012-1009-x.

DOI:10.1007/s12185-012-1009-x
PMID:22302471
Abstract

We retrospectively analyzed patients aged C 50 years with hematologic malignancies who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) to identify preoperative variables predicting the outcome. There were 71 patients with a median age of 57 years (range: 50-63 years) who had acute leukemia (n = 53) or myelodysplastic syndrome (n = 18). Myeloablative conditioning was done in 35 patients and 36 patients had reduced-intensity conditioning. The 5-year overall survival rate (OS), cumulative relapse rate, and non-relapse mortality rate (NRM) were 45, 24, and 33%, respectively. According to multivariate analysis, high-risk disease (HR 3.50, 95% CI 1.43-8.56, P = 0.006), a hematopoietic cell transplantation comorbidity index (HCT-CI) score ≥ 3 (HR 4.41, 95% CI 1.31-14.77, P = 0.016), and an HLA-mismatched unrelated donor (HR 4.03, 95% CI 1.46-11.10, P = 0.007) were significant predictors of worse OS. Highrisk disease was also significantly associated with a higher cumulative relapse rate (HR 4.59, 95% CI 0.94-6.92, P = 0.065). Furthermore, an HCT-CI score ≥ 3 (HR 3.02, 95% CI 1.01-20.78, P = 0.048) and an HLA-mismatched unrelated donor (HR 3.02, 95% CI 1.04-8.74, P = 0.042) were risk factors for NRM. These results suggest that the disease risk, HCT-CI score, and donor type/histocompatibility are prognostic factors for elderly patients, while the conditioning regimen and age are not predictors.

摘要

我们回顾性分析了年龄在 50 岁以上的接受异基因造血干细胞移植(allo-HSCT)的血液恶性肿瘤患者,以确定预测结局的术前变量。共有 71 例中位年龄为 57 岁(范围:50-63 岁)的患者,其中急性白血病(n=53)或骨髓增生异常综合征(n=18)。35 例患者接受了清髓性预处理,36 例患者接受了强度降低预处理。5 年总生存率(OS)、累积复发率和非复发死亡率(NRM)分别为 45%、24%和 33%。根据多变量分析,高危疾病(HR 3.50,95%CI 1.43-8.56,P=0.006)、造血细胞移植合并症指数(HCT-CI)评分≥3(HR 4.41,95%CI 1.31-14.77,P=0.016)和 HLA 不匹配的无关供体(HR 4.03,95%CI 1.46-11.10,P=0.007)是 OS 较差的显著预测因素。高危疾病也与更高的累积复发率显著相关(HR 4.59,95%CI 0.94-6.92,P=0.065)。此外,HCT-CI 评分≥3(HR 3.02,95%CI 1.01-20.78,P=0.048)和 HLA 不匹配的无关供体(HR 3.02,95%CI 1.04-8.74,P=0.042)是 NRM 的危险因素。这些结果表明,疾病风险、HCT-CI 评分和供体类型/组织相容性是老年患者的预后因素,而预处理方案和年龄不是预测因素。

相似文献

1
Prognostic factors in patients aged 50 years or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancy.50 岁及以上血液恶性肿瘤患者行异基因造血干细胞移植的预后因素。
Int J Hematol. 2012 Mar;95(3):291-8. doi: 10.1007/s12185-012-1009-x.
2
Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy.造血细胞移植特异性合并症指数(HCT-CI)能否预测移植结局?日本关东地区细胞治疗研究组的一项前瞻性多中心验证研究。
Biol Blood Marrow Transplant. 2014 Oct;20(10):1553-9. doi: 10.1016/j.bbmt.2014.06.005. Epub 2014 Jul 15.
3
A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.在现代时代,异体干细胞移植中氟达拉滨/白消安与环磷酰胺/全身照射的清髓性调理方案比较:队列分析。
Biol Blood Marrow Transplant. 2018 Aug;24(8):1733-1740. doi: 10.1016/j.bbmt.2018.03.011. Epub 2018 Mar 16.
4
Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies.小儿复发性血液系统恶性肿瘤患者第二次造血干细胞移植后的结局
Biol Blood Marrow Transplant. 2015 Jul;21(7):1266-72. doi: 10.1016/j.bbmt.2015.02.024. Epub 2015 Mar 10.
5
Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.比较两种移植前预测模型和使用不同截断点的灵活 HCT-CI,以确定低、中、高危组:在接受 allo-RIC 的患者人群中,灵活 HCT-CI 是 NRM 和 OS 的最佳预测因子。
Biol Blood Marrow Transplant. 2010 Mar;16(3):413-20. doi: 10.1016/j.bbmt.2009.11.008. Epub 2009 Nov 14.
6
Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.联合造血细胞移植合并症指数和欧洲血液与骨髓移植组评分可更好地对接受低强度异基因造血细胞移植的高危患者进行分层。
Biol Blood Marrow Transplant. 2014 Jan;20(1):66-72. doi: 10.1016/j.bbmt.2013.10.011. Epub 2013 Oct 17.
7
Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.HLA 匹配相关异基因造血干细胞移植中风险评分系统的比较:一项回顾性队列研究。
Turk J Haematol. 2021 Jun 1;38(2):138-144. doi: 10.4274/tjh.galenos.2020.2020.0178. Epub 2020 Jun 16.
8
Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: A single center study.首次造血干细胞移植后复发的血液病患者进行第二次造血异体干细胞移植的预后因素:一项单中心研究。
Front Immunol. 2023 Jan 4;13:1066748. doi: 10.3389/fimmu.2022.1066748. eCollection 2022.
9
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.异基因反应性作为血液系统恶性肿瘤治疗的治疗原则。非清髓性预处理的异基因造血细胞移植的临床和免疫学方面的研究。
Dan Med Bull. 2007 May;54(2):112-39.
10
[Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].造血细胞移植特异性合并症指数对异基因造血干细胞移植后非复发死亡率和总生存率的预后影响
Zhonghua Xue Ye Xue Za Zhi. 2013 Aug;34(8):659-63. doi: 10.3760/cma.j.issn.0253-2727.2013.08.004.

引用本文的文献

1
Association between the pre-transplantation serum ferritin level and outcomes of hematopoietic stem cell transplantation: A systematic review and meta-analysis.移植前血清铁蛋白水平与造血干细胞移植结局之间的关联:一项系统评价和荟萃分析。
Heliyon. 2024 Sep 4;10(18):e37436. doi: 10.1016/j.heliyon.2024.e37436. eCollection 2024 Sep 30.
2
Cardiovascular events among recipients of hematopoietic stem cell transplantation-A systematic review and meta-analysis.造血干细胞移植受者的心血管事件:系统评价和荟萃分析。
Bone Marrow Transplant. 2023 May;58(5):478-490. doi: 10.1038/s41409-023-01928-2. Epub 2023 Feb 27.
3

本文引用的文献

1
Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation.在接受低强度预处理的造血祖细胞移植的骨髓增生异常综合征和白血病患者中,HCT 合并症指数、移植时年龄和疾病状态在预测生存和非复发死亡率中的作用。
Bone Marrow Transplant. 2012 Apr;47(4):528-34. doi: 10.1038/bmt.2011.138. Epub 2011 Jul 11.
2
Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT.回顾性分析接受低强度预处理方案和同种异体造血干细胞移植治疗且年龄大于 60 岁患者的常见评分系统和结局。
Bone Marrow Transplant. 2011 Jul;46(7):1000-5. doi: 10.1038/bmt.2010.227. Epub 2010 Oct 4.
3
Hematopoietic Cell Transplant (HCT) in the Elderly: Myths, Controversies and Unknowns.
老年造血细胞移植:误区、争议与未知
Drugs Aging. 2018 Dec;35(12):1055-1064. doi: 10.1007/s40266-018-0596-5.
4
Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.急性髓系白血病和急性淋巴细胞白血病患者异基因造血干细胞移植中减低强度与清髓性预处理方案的比较:一项荟萃分析
Stem Cells Dev. 2014 Nov 1;23(21):2535-52. doi: 10.1089/scd.2014.0123. Epub 2014 Sep 17.
5
Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic.老年血液系统恶性肿瘤的造血干细胞移植:移植临床中的老年医学原则。
J Natl Compr Canc Netw. 2014 Jan;12(1):128-36. doi: 10.6004/jnccn.2014.0010.
6
IgM anti-recipient ABO antibodies predict acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.IgM 抗供体 ABO 抗体预测异基因造血干细胞移植后急性移植物抗宿主病。
Int J Hematol. 2013 Jul;98(1):96-101. doi: 10.1007/s12185-013-1360-6. Epub 2013 May 10.
7
To transplant or not to transplant for adult acute myeloid leukemia: an ever-evolving decision.成人急性髓系白血病是否进行移植:一个不断演变的决策。
Clin Adv Hematol Oncol. 2012 Oct;10(10):655-62.
Prognostic factors in allo-SCT of elderly patients with AML.老年 AML 患者 allo-SCT 的预后因素。
Bone Marrow Transplant. 2011 Apr;46(4):545-51. doi: 10.1038/bmt.2010.145. Epub 2010 Jun 14.
4
Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.年龄对缓解后接受低强度造血细胞移植的老年急性髓系白血病或骨髓增生异常综合征患者的预后的影响。
J Clin Oncol. 2010 Apr 10;28(11):1878-87. doi: 10.1200/JCO.2009.25.4821. Epub 2010 Mar 8.
5
Unrelated transplantation for poor-prognosis adult acute lymphoblastic leukemia: long-term outcome analysis and study of the impact of hematopoietic graft source.无关供者移植治疗预后不良的成人急性淋巴细胞白血病:长期结果分析及造血移植物来源影响的研究。
Biol Blood Marrow Transplant. 2010 Jul;16(7):957-66. doi: 10.1016/j.bbmt.2010.02.003. Epub 2010 Feb 7.
6
Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study.移植前合并症对疾病状态和移植后时间的移植结局的预后影响差异:单日本移植中心研究。
Bone Marrow Transplant. 2010 Mar;45(3):513-20. doi: 10.1038/bmt.2009.194. Epub 2009 Aug 17.
7
Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.异基因造血干细胞移植后结局的风险评分:一项回顾性分析
Cancer. 2009 Oct 15;115(20):4715-26. doi: 10.1002/cncr.24531.
8
Elevated pretransplant serum ferritin is associated with inferior survival following nonmyeloablative allogeneic transplantation.移植前血清铁蛋白升高与非清髓性异基因移植后的较差生存率相关。
Bone Marrow Transplant. 2009 Dec;44(11):767-8. doi: 10.1038/bmt.2009.77. Epub 2009 Apr 20.
9
The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.造血细胞移植合并症指数(HCT-CI)可预测淋巴瘤和骨髓瘤患者在接受减低强度或非清髓性异基因干细胞移植后的临床结局。
Leukemia. 2009 Jun;23(6):1131-8. doi: 10.1038/leu.2009.1. Epub 2009 Feb 5.
10
HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism.与复发风险降低相关的HLA错配组合:对分子机制的启示
Blood. 2009 Mar 19;113(12):2851-8. doi: 10.1182/blood-2008-08-171934. Epub 2008 Nov 7.